دورية أكاديمية
أعرض في EDS

Acquired hemophilia A and other autoimmune diseases after alemtuzumab therapy for multiple sclerosis: A report of two cases.

التفاصيل البيبلوغرافية
العنوان: Acquired hemophilia A and other autoimmune diseases after alemtuzumab therapy for multiple sclerosis: A report of two cases.
المؤلفون: Comini-Frota ER; Universidade José do Rosário Vellano, Belo Horizonte, MG, Brazil., Campos APF; Academic of Medicine at Universidade José do Rosário Vellano, Belo Horizonte, MG, Brazil., Neto APG; Neurology Department, Santa Casa de Misericórdia Belo Horizonte, Brazil., Christo PP; Department of Internal Medicine, Universidade Federal de Minas Gerais. Instituto de Ensino e Pesquisa, Santa Casa de Misericórdia de Belo Horizonte, MG, Brazil.. Electronic address: ppchristo@gmail.com.
المصدر: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2020 Sep; Vol. 44, pp. 102181. Date of Electronic Publication: 2020 May 21.
نوع المنشور: Case Reports; Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B. V Country of Publication: Netherlands NLM ID: 101580247 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-0356 (Electronic) Linking ISSN: 22110348 NLM ISO Abbreviation: Mult Scler Relat Disord Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B. V.
مواضيع طبية MeSH: Autoimmune Diseases* , Hemophilia A*/chemically induced , Hemophilia A*/diagnosis , Multiple Sclerosis*, Alemtuzumab/adverse effects ; Brazil ; Humans
مستخلص: Alemtuzumab (ALZ) is an anti-CD52 monoclonal antibody used to treat recurrent remittent multiple sclerosis (RRMS). After ALZ infusion, there is a depletion of T and B cells expressing CD52, while the stem cells and innate immune cells are spared. Longitudinal studies with long periods of follow-ups have reported ALZ-associated autoimmune diseases, such as thrombocytopenic purpura and thyroiditis. We report two patients who developed autoimmune hemophilia A or acquired hemophilia (AHA) after ALZ infusion, one of whom developed severe vitiligo. To the best of our knowledge, these two cases of ALZ-associated AHA are the first two cases to be reported in Brazil, and the fourth and fifth AHA cases to be reported worldwide. AHA is a potential life-threatening disease if not diagnosed and treated in a timely manner. The development of AHA should be cited as a possible adverse event, and specific coagulation tests must be part of the official recommendations for patient follow-ups.
(Copyright © 2020 Elsevier B.V. All rights reserved.)
فهرسة مساهمة: Keywords: Acquired hemophilia A; Alemtuzumab; Autoimmune diseases; Multiple sclerosis; Vitiligo
المشرفين على المادة: 3A189DH42V (Alemtuzumab)
تواريخ الأحداث: Date Created: 20200613 Date Completed: 20210514 Latest Revision: 20210514
رمز التحديث: 20240628
DOI: 10.1016/j.msard.2020.102181
PMID: 32531751
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا